LY-334370

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H22FN3O
Molecular Weight	351.4173
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CN1CCC(CC1)C2=CNC3=C2C=C(NC(=O)C4=CC=C(F)C=C4)C=C3

InChI

InChIKey=MDMJLMDBRQXOOI-UHFFFAOYSA-N

InChI=1S/C21H22FN3O/c1-25-10-8-14(9-11-25)19-13-23-20-7-6-17(12-18(19)20)24-21(26)15-2-4-16(22)5-3-15/h2-7,12-14,23H,8-11H2,1H3,(H,24,26)

HIDE SMILES / InChI

Description

LY-334370 is a selective agonist at the serotonin 1F receptor. Lilly had been conducting phase II clinical testing of this compound in Europe as a potential therapy for migraine headaches. Lilly has now announced that it has discontinued commercial development of LY 334370 as a result of a review of data from an ongoing animal toxicology study. It was reported that the compound causes G-protein activation that is mediated by 5-HT1A receptors.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 1f (5-HT1f) receptor 15	Agonist 2,752		0.446 nM [Kd]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Migraine 107	Primary		Phase II 1,147	Unknown

Doses

Show entries

Dose	Population	Adverse events
200 mg single, oral Highest studied dose	unhealthy, ADULT	Other AEs: Asthenia, Dizziness...

Showing 1 to 1 of 1 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Paresthesia	19%	200 mg single, oral Highest studied dose	unhealthy, ADULT
Somnolence	23%	200 mg single, oral Highest studied dose	unhealthy, ADULT
Asthenia	27%	200 mg single, oral Highest studied dose	unhealthy, ADULT
Dizziness	35%	200 mg single, oral Highest studied dose	unhealthy, ADULT

Showing 1 to 4 of 4 entries

Previous1Next

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P00AL83	https://www.1pchem.com/search?query=1P00AL83
AChemBlock	Q70200	http://www.achemblock.com/catalogsearch/result/?q=Q70200
Angene	AGN-PC-02ISQ2	http://www.angenechemical.com/productshow/AGN-PC-02ISQ2.html
ApexBio Technology	B7267	https://www.apexbt.com/catalogsearch/result/?q=B7267
Axon MedChem	1612	https://www.axonmedchem.com/product/1612

Showing 1 to 5 of 26 entries

Previous1 2 3 4 5 6Next

PubMed

Show entries

Title	Date	PubMed
G-protein activation at 5-HT1A receptors by the 5-ht1F ligand LY334370 in guinea-pig brain sections and recombinant cell lines.	1998 May	9641544
Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370.	1999 Dec	10668103
Ligands for the investigation of 5-HT autoreceptor function.	2001 Nov 15	11750791
Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial.	2001 Oct 13	11675061
Crystal forms of LY334370 HCl: isolation, solid-state characterization, and physicochemical properties.	2003 Jun	12761809

Showing 1 to 5 of 10 entries

Previous1 2Next

Patents

Sample Use Guides

In Vivo Use Guide

LY334370 (20, 60, or 200 mg) was given to outpatients with moderate or severe migraine headaches in a double blind, parallel group study

Route of Administration: Oral

In Vitro Use Guide

1–100 nM LY334370 increased carbonylcyanide-p-trifluoromethoxyphenylhydrazone–uncoupled oxygen consumption in renal proximal tubule cells

Show entries

Name

Type

Language

LY-334370

Code

English

BENZAMIDE, 4-FLUORO-N-(3-(1-METHYL-4-PIPERIDINYL)-1H-INDOL-5-YL)-

Preferred Name

English

4-FLUORO-N-(3-(1-METHYLPIPERIDIN-4-YL)-1H-INDOL-5-YL)BENZAMIDE

Systematic Name

English

LY334370

Code

English

Showing 1 to 4 of 4 entries

Previous1Next

Show entries

Code System

Code

Type

Description

CAS

182563-08-2

PRIMARY

FDA UNII

5Q7I1WL2UY

PRIMARY

WIKIPEDIA

LY-334370

PRIMARY

PUBCHEM

5311258

PRIMARY

EPA CompTox

DTXSID40415518

PRIMARY

Showing 1 to 5 of 5 entries

Previous1Next

SUBSTANCE RECORD


					5Q7I1WL2UY

LY-334370